- Revenue fell to Rs 7,516 crore in Q4 FY26 from Rs 8,506 crore in Q4 FY25, registering a YoY decline of 11.6 per cent.
- Profit dropped sharply to Rs 220.5 crore from Rs 1,587 crore, a steep YoY decline of 86.1 per cent.
- EBITDA decreased to Rs 980 crore from Rs 2,475 crore, down 60.4% year-on-year.
- EBITDA Margin contracted sharply from 29.1 per cent to 13 per cent, a decline of 1,605.9 basis points.
G V Prasad, Co-Chairman & MD, said, “Our performance this year reflects the impact of lower lenalidomide sales and several one-offs. The resilience of our branded businesses and currency tailwinds helped partially mitigate this impact. We remain focused on strengthening our base business and improving margins, through cost efficiencies and portfolio optimization. In parallel, we continue to build long-term franchises in biosimilars, consumer health and innovation to deliver sustainable value.”
